Table .

2 Outcomes important to patients in decision to use rosiglitazone to prevent diabetes

End point	Rosiglitazone (n=10 000)	No rosiglitazone (n=10 000)	Hazard ratio (95% CI )
Drug use
Patient years of use of ≥1 diabetes drug at end of trial (3 years)	30 000	3 650	—
No of patients with new diagnosis of diabetes at end of trial (3 years)*	1060	2500	0.38 (0.33 to 0.44)
Projected patient years taking ≥1 diabetes drug at 10 years, assuming 3% annual incidence of diabetes	43 637	33 856	—
Projected patient years taking ≥1 diabetes drug at 10 years, assuming 8% annual incidence of diabetes	52 566	33 856	—
Diabetes related outcomes
Anxiety about diabetes	?	?	?
Costs and inconvenience associated with glucose self monitoring	?	?	?
Costs and inconvenience associated with medical care	?	?	?
Cardiovascular end points (myocardial infarction, stroke, cardiovascular death) at 3 years	120	90	1.39 (0.81 to 2.37)
Cardiovascular end points at 10 years	?	?	?
Heart failure at 3 years	50	10	7.03 (1.6 to 30.9)
Heart failure at 10 years	?	?	?
Retinopathy, nephropathy, or neuropathy	?	?	?
Common adverse effects
Peripheral oedema at 3 years	680	490	1.4§(1.1 to 1.8)
Weight gain (kg) at 3 years †	2.0	−0.2	—
Peripheral oedema or weight gain at 10 years	?	?	?
Rare adverse effects
Bone fractures at 4 years‡	632	373	1.7§ (1.3 to 2.2)
Macular oedema	?	?	?

*Assuming that clinicians immediately prescribe diabetes drugs (metformin) to patients who have diabetes diagnosed given that they were already receiving limited lifestyle interventions in DREAM.

†from the DREAM slide set (www.ccc.mcmaster.ca/dream.htm).

‡From the ADOPT trial¹⁸

§Risk ratio.